HOME  >  R&D

GeneMedicine Oncolytic Adenovirus

GeneMedicine Oncolytic Adenovirus

GM Oncolytic Virus exhibits superior attributes in respect to conventional or competitor oncolytic viruses

Cancer specificity
  • · Precise genetic engineering enabled GM oncolytic virus to elicit cancer cell killing effect in a highly can­cer-specific manner
Safety profile
  • · Excellent cancer specificity of GM oncolytic virus minimizes non-specific viral replication in normal tissues, thus greatly improving its safety profile
Viral replication
  • · GM oncolytic virus exhibits an exponentially higher level of viral replication in tumor tissues, compared with other competing oncolytic viruses.
  • · Superior viral replication of GM oncolytic virus in tumor cells enhances secondary and tertiary infection to adjacent tumor cell population, thus leading to a potent anticancer effect
Targeting diverse oncogenic signaling pathways
  • · Most conventional oncolytic viruses either completely lack or possess only a single therapeutic transgene. In sharp contrast, a single GM oncolytic virus can co-express up to 4 different therapeutic transgenes, thus allows to simultaneously target multiple oncogenic signaling pathways to maximize therapeutic efficacy.
Cancer killing effect
  • · Excellent tumor specificity, viral replication capacity, and ability to simultaneously target multiple oncogenic signaling pathways result in potent antitumor effect mediated by GM oncolytic virus
Systemically administrable technology
  • · Systemic administration remains a major technical limitation of oncolytic viruses. In contrast, the original platform technology of GeneMedicine Co., Ltd. which combines GM oncolytic virus with tumor-target­ed nanomaterials, can efficiently evade host immune recognition and enable tumor-targeted systemic delivery of oncolytic virus.
TOP